Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $283.00.
A number of equities analysts recently commented on the stock. StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler boosted their price target on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th.
Read Our Latest Stock Report on BDX
Becton, Dickinson and Company Price Performance
Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a net margin of 8.55% and a return on equity of 14.89%. The company had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the prior year, the business earned $3.42 EPS. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and Company will post 14.41 EPS for the current fiscal year.
Becton, Dickinson and Company announced that its Board of Directors has authorized a stock repurchase program on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase programs are usually an indication that the company’s board believes its shares are undervalued.
Becton, Dickinson and Company Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, March 31st. Investors of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.68%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 70.03%.
Insider Transactions at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the business’s stock in a transaction dated Friday, December 6th. The stock was sold at an average price of $221.01, for a total transaction of $990,787.83. Following the sale, the executive vice president now owns 24,345 shares in the company, valued at approximately $5,380,488.45. The trade was a 15.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP David Shan sold 500 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total value of $120,000.00. Following the completion of the transaction, the executive vice president now owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 9,844 shares of company stock worth $2,210,716. Insiders own 0.36% of the company’s stock.
Hedge Funds Weigh In On Becton, Dickinson and Company
A number of institutional investors have recently bought and sold shares of the business. Livelsberger Financial Advisory acquired a new stake in shares of Becton, Dickinson and Company in the third quarter worth $26,000. Bank of Jackson Hole Trust acquired a new stake in Becton, Dickinson and Company during the 4th quarter worth about $25,000. Sierra Ocean LLC purchased a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at about $29,000. Ashton Thomas Securities LLC acquired a new position in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $33,000. Finally, Tompkins Financial Corp grew its holdings in Becton, Dickinson and Company by 44.2% during the third quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 46 shares during the period. 86.97% of the stock is owned by hedge funds and other institutional investors.
About Becton, Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Recommended Stories
- Five stocks we like better than Becton, Dickinson and Company
- Growth Stocks: What They Are, What They Are Not
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Microsoft and Meta’s AI Investment Plans Are Full Steam Ahead
- Health Care Stocks Explained: Why You Might Want to Invest
- Beyond Self-Driving Cars: Factory Automation Takes Center Stage
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.